Search

Your search keyword '"Villa, Chet R."' showing total 22 results
Start Over Author "Villa, Chet R." Search Limiters Available in Library Collection
22 results on '"Villa, Chet R."'

1. Multicenter outcomes for ventricular assist device support for failed stage II palliation

Author

Rabinowitz, Edon J., Mehegan, Mary, Joong, Anna, Shezad, Muhammad, Lorts, Angela, Villa, Chet R., Conway, Jennifer, Kobayashi, Ryan, Auerbach, Scott R., Zinn, Matthew, Niebler, Robert, Iqbal, Mehreen, Dykes, John, Choudhry, Swati, Aljohani, Othman, Absi, Mohammed, Ploutz, Michelle S., Griffiths, Eric R., O’Connor, Matthew J., Mokshagundam, Deepa, and Said, Ahmed S.

Published
2024
Full Text
View/download PDF

4. Abdominal CT and MRI Findings of Portal Hypertension in Children and Adults with Fontan Circulation

Author

Zafar, Faizeen, primary, Lubert, Adam M., additional, Trout, Andrew T., additional, Katz, David A., additional, Palermo, Joseph J., additional, Opotowsky, Alexander R., additional, Lorts, Angela, additional, Chin, Clifford, additional, Powell, Adam W., additional, Villa, Chet R., additional, Anwar, Nadeem, additional, Morales, David L., additional, Dillman, Jonathan R., additional, and Alsaied, Tarek, additional

Published
2022
Full Text
View/download PDF

9. ABCs of Stroke Prevention

Author

Villa, Chet R, primary, VanderPluym, Christina J, additional, Lorts, Angela, additional, Morales, David L.S., additional, Zafar, Farhan, additional, Krack, Paige, additional, Smyth, Lauren, additional, Fields, Katrina, additional, Rosenthal, David N., additional, Murray, Jenna, additional, Hawkins, Beth, additional, Peng, David M., additional, Sutcliffe, David L., additional, Lantz, Jodie, additional, Auerbach, Scott R., additional, Williams, Meghan, additional, O’Connor, Matthew, additional, White, Rachel, additional, Niebler, Robert A., additional, Pearce, F. Bennet, additional, Hubbard, Meloneysa, additional, Zinn, Matthew, additional, Reichhold, Allison, additional, Joong, Anna, additional, Bearl, David, additional, Nandi, Deipanjan, additional, Gajarski, Robert, additional, Ploutz, Michelle, additional, May, Lindsay J., additional, Mehegan, Mary, additional, Simpson, Kathleen, additional, Conway, Jennifer, additional, Dubyk, Nicole, additional, Tunuguntla, Hari, additional, Elias, Barbara, additional, Jeewa, Aamir, additional, Gossett, Jeffrey G., additional, and Gowen, Mary, additional

Published
2020
Full Text
View/download PDF

19. Transplant Outcomes for Congenital Heart Disease Patients Bridged With a Ventricular Assist Device.

Author

IIIBryant, Roosevelt, Rizwan, Raheel, Villa, Chet R., Zafar, Farhan, Wells, Dennis, Chin, Clifford, Lorts, Angela, and Morales, David L.

Abstract

Background Ventricular assist device (VAD) use as a bridge to transplant (BTT) for children with end-stage heart failure and congenital heart disease (CHD), although challenging, has increased, but its effect on posttransplant outcome is unknown. This study describes posttransplant outcomes of CHD patients BTT with a VAD. Methods All heart transplant recipients identified in United Network of Organ Sharing database from 2006 to 2015 (n = 21,865) were divided into four groups by those with (+) and without (–) a diagnosis of CHD and with (+) and without (–) VAD support at transplant: +CHD/+VAD, +CHD/–VAD, +VAD/–CHD, and –VAD/–CHD. Posttransplant survival of +CHD/+VAD was compared with +CHD/–VAD, –CHD/+VAD, and –CHD/–VAD in addition to pretransplant characteristics comparison between +CHD/+VAD and +CHD/–VAD. Results Of 1,871 patients (8.6%) with CHD, 1,348 (72%) were younger than 18 years old, and 143 (7.6%) were BTT with a VAD (+CHD/+VAD). At transplant, +CHD/+VAD compared with +CHD/–VAD were more likely to have worse functional status (<50%: 60% vs 46%, p = 0.004), infections (29% vs 14%, p < 0.001), to be sensitized (47% vs 30%, p < 0.001) and on ventilator support (20% vs 13%, p = 0.029) and dialysis (13% vs 2.5%, p < 0.001). Overall, 1-year (84% vs 87%) and 5-year (72% vs 75%) survival was similar for +CHD/+VAD and +CHD/–VAD ( p = 0.694). Survival was also similar when +CHD/+VAD were compared with –CHD/+VAD (n = 7,363; p = 0.529) and –CHD/–VAD (n = 12,613; p = 0.097). Conclusions Although more ill pretransplant, CHD patients BTT with a VAD have similar posttransplant survival compared with CHD patients without a VAD and with other non–CHD heart transplant patients. VAD support may mitigate certain risk factors for poor posttransplant outcomes in the challenging CHD cohort. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

20. Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and Is Associated With Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy

Author

Tandon, Animesh, primary, Villa, Chet R., additional, Hor, Kan N., additional, Jefferies, John L., additional, Gao, Zhiqian, additional, Towbin, Jeffrey A., additional, Wong, Brenda L., additional, Mazur, Wojciech, additional, Fleck, Robert J., additional, Sticka, Joshua J., additional, Benson, D. Woodrow, additional, and Taylor, Michael D., additional

Published
2015
Full Text
View/download PDF

21. Abstract 12450: Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and is Modified by Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy

Author

Tandon, Animesh, primary, Villa, Chet R, additional, Hor, Kan N, additional, Jefferies, John L, additional, Gao, Zhiqian, additional, Towbin, Jeffrey A, additional, Wong, Brenda L, additional, Mazur, Wojciech, additional, Fleck, Robert J, additional, Sticka, Joshua J, additional, Benson, Dudley W, additional, and Taylor, Michael D, additional

Published
2014
Full Text
View/download PDF

22. Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy.

Author

Villa CR, Czosek RJ, Ahmed H, Khoury PR, Anderson JB, Knilans TK, Jefferies JL, Wong B, and Spar DS

Subjects
Adolescent, Age Factors, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac mortality, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac therapy, Atrial Fibrillation diagnosis, Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Atrial Flutter diagnosis, Atrial Flutter etiology, Atrial Flutter physiopathology, Cardiomyopathy, Dilated diagnosis, Cardiomyopathy, Dilated mortality, Cardiomyopathy, Dilated physiopathology, Chi-Square Distribution, Child, Female, Humans, Logistic Models, Male, Muscular Dystrophy, Duchenne diagnosis, Muscular Dystrophy, Duchenne mortality, Predictive Value of Tests, Prognosis, Retrospective Studies, Risk Factors, Stroke Volume, Tachycardia, Supraventricular diagnosis, Tachycardia, Supraventricular etiology, Tachycardia, Supraventricular physiopathology, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular etiology, Tachycardia, Ventricular physiopathology, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left mortality, Ventricular Dysfunction, Left physiopathology, Ventricular Function, Left, Ventricular Premature Complexes diagnosis, Ventricular Premature Complexes etiology, Ventricular Premature Complexes physiopathology, Young Adult, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac etiology, Cardiomyopathy, Dilated etiology, Electrocardiography, Ambulatory, Heart Rate drug effects, Muscular Dystrophy, Duchenne complications, Ventricular Dysfunction, Left etiology
Abstract

Background: Patients with Duchenne Muscular Dystrophy (DMD) develop cardiac fibrosis and dilated cardiomyopathy. We described the frequency of significant Holter findings in DMD, the relationship between cardiac function and arrhythmia burden, and the impact of these findings on clinical management., Methods and Results: A retrospective review was done of patients with DMD who received a Holter from 2010 to 2014. Clinical and arrhythmic outcomes were analyzed. Patients were classified based on left ventricular ejection fraction (LVEF): ≥55%, 35% to 54% and <35%. Significant Holter findings included atrial tachycardia, ventricular tachycardia and atrial fibrillation/flutter. Logistic regression was used to assess predictors of significant Holter findings and change in care. The study included 442 Holters in 235 patients. Mean age was 14±4 years. Patients with cardiac dysfunction were older, and had increased late gadolinium enhancement and left ventricular dilation (P<0.01). There were 3 deaths (1%), all with normal function and none cardiac. Patients with LVEF <35% had more arrhythmias including nonsustained atrial tachycardia (P=0.01), frequent premature ventricular contractions, ventricular couplets/triplets, and nonsustained ventricular tachycardia (P<0.001) compared to the other groups. LVEF <35% (P<0.001) was the only predictor of clinically significant Holter finding. Four patients (40%) had change in medication in the LVEF <35% group compared to 9 (3%) in the ≥55% and 4 (4%) in the 35% to 54% groups (P<0.001)., Conclusions: Sudden cardiac events are rare in DMD patients with an LVEF >35%. Significant Holter findings are rare in patients with DMD who have an LVEF >35%, and cardiac dysfunction appears to predict significant Holter findings. Holter monitoring is highest yield among DMD patients with cardiac dysfunction., (© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results